Lifeboat Foundation

In experiments in mice, Johns Hopkins Medicine researchers say they have developed a way to successfully transplant certain protective brain cells without the need for lifelong anti-rejection drugs.

A report on the research, published Sept. 16 in the journal Brain, details the new approach, which selectively circumvents the immune response against foreign cells, allowing transplanted cells to survive, thrive and protect brain tissue long after stopping immune-suppressing drugs.

The ability to successfully transplant healthy cells into the brain without the need for conventional anti-rejection drugs could advance the search for therapies that help children born with a rare but devastating class of genetic diseases in which myelin, the protective coating around neurons that helps them send messages, does not form normally. Approximately 1 of every 100,000 children born in the U.S. will have one of these diseases, such as Pelizaeus-Merzbacher disease. This disorder is characterized by infants missing developmental milestones such as sitting and walking, having involuntary muscle spasms, and potentially experiencing partial paralysis of the arms and legs, all caused by a genetic mutation in the genes that form myelin.

Recent genome-wide association studies have catapulted the search for genes underlying human intelligence into a new era. Genome-wide polygenic scores promise to transform research on individual differences in intelligence, but not without societal and ethical implications, as the authors discuss in this Review.

Are humans born with “intelligence” genes, or is human intelligence determined by environmental factors, such as economic status or easy access to education?

When a team of researchers set out to answer this question, they discovered that more than 500 genes were associated with intelligence. The results, published in Nature Genetics, indicate that intelligence is much more complex than previously thought.

Continue reading “More than 500 Intelligence Genes Discovered” »

Today, we’re offering another talk from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

In her talk, Morgan Levine of the Yale School of Medicine discussed epigenetic biomarkers in detail, discussing the ways in which co-methylation networks provide insight into senescent cells and other facets of biological age.

A deadly fungus is spreading through banana plantations, and the cloned bananas we eat are defenseless. In labs around the world, scientists are trying to find ways to genetically alter the fruit to make it resistant.

[Images: Rawpixel]

Scientists are reporting the first use of the gene-editing tool CRISPR to try to cure a patient’s HIV infection by providing blood cells that were altered to resist the AIDS virus.

The gene-editing tool has long been used in research labs and a Chinese scientist was scorned last year when he revealed he used it on embryos that led to the birth of twin girls. Editing embryos is considered too risky, partly because the DNA changes can pass to future generations.

Wednesday’s report in the New England Journal of Medicine, by different Chinese researchers, is the first published account of using CRISPR to treat a disease in an adult, where the DNA changes are confined to that person.

Evidence that quantum searches are an ordinary feature of electron behavior may explain the genetic code, one of the greatest puzzles in biology.

In July of 2017, doctors in Beijing blasted the patient with chemicals and radiation to wipe out his bone marrow, making space for millions of stem cells they then pumped into his body through an IV. These new stem cells, donated by a healthy fellow countryman, would replace the patient’s unhealthy ones, hopefully resolving his cancer. But unlike any other routine bone marrow transplant, this time researchers edited those stem cells with Crispr to cripple a gene called CCR5, without which HIV can’t infiltrate immune cells.

For the first time, a patient got treated for HIV and cancer at the same time, with an infusion of gene-edited stem cells. The results? Mixed.